Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy

NCT00106392 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00106392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Prograf (Tacrolimus, FK 506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-sparing Radical Prostatectomy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2005
Completion date
November 30, 2008
Enrollment
131 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction, prostate cancer